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Abstract. The paper investigates the role of dynamic externalities, university-industry 
linkages and role of social networking in the biotechnology industry in the European 
Union (EU). Universities act as platforms for local knowledge spillovers and university-
industry cluster development in the biotechnology field. The R&D activities at 
universities contribute to successful business innovations. However, the relationship 
between the universities and the local innovation capabilities is much more complex 
and therefore requires more in-depth analysis. The following study derives from the 
knowledge of the new economic geography, endogenous growth theory, biotechnology, 
as well as theories of social capital and social networks. The quantitative research 
elaborates contemporary literature and databases to find channels of interdependence 
between local university-based knowledge flows, social capital, and biotechnology 
cluster performance. The results of the study show that the biotechnology industry 
relies very much on university-business R&D partnerships and research mobility (e.g. 
pharmaceutical firms that performed basic research in close cooperation with 
academia produced more patents). In addition, social networking and informal 
contacts seem to be a more important for the diffusion of knowledge, especially at the 
beginning of R&D process, as they allow for building credibility between potential 
partners. 
 
Keywords: industrial biotechnology, knowledge spillovers, clusters, regional 
development.  
 
 
Introduction  
 
Smart specialization has been highlighted in the latest Europe 2020 Growth 
Strategy and Cohesion Policy 2014-2020. Both documents place smart 
specialization to the bottom-up entrepreneurial discovery process about a 
region’s assets, its challenges, competitive advantages and the potential for 
excellence (European Commission, 2012). In this approach of priority-
setting of the region`s specialization, local dynamic externalities, social 
networks, and university-industry collaborations play a crucial role. The role 
of social collaboration networks seems to be even more important in the 
case of such dynamic industries as biotechnology, where research is more 
complex and interdisciplinary. As Emanuela Todeva (2013) puts it, the smart 
specialization, in this context, is a function of the university-industry 
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interactions, and the acceleration of knowledge transfer practices, such as 
spin-offs, start-ups, contract research.  
 
The following paper investigates the ways in which proximity to universities 
enhances social networking and informal contacts in the biotechnology 
industry, and thus enhances region`s innovative capabilities and smart 
specialization development. The research study addresses the following 
research questions: Where is the biotechnology industry concentrated in the 
EU? Which cluster (dynamic) externalities are predominant in the EU 
biotechnology clusters? What are the linkages between the biotechnology 
industry development and the university R&D labs? What is the role of social 
capital in the knowledge spillovers in the biotechnology industry in the EU? 
 
The research study covers the period from 1997 up to the latest accessible 
data. The first section of the research papers aims to identify based on the 
subject literature, the theoretical linkages between the clusters, dynamic 
externalities and social networking. The second section of the paper focuses 
more specifically on the biotechnology industry drivers of development, 
technological externalities as well as on mapping biotechnology clusters in 
the EU. Finally, the last part presents the overview of the empirical studies 
results on the role of universities and social networking in the localized 
knowledge spillovers and innovation capabilities in the biotechnology 
industry. The research paper ends with relative conclusions and policy 
recommendations. 
 
 
Clusters, dynamic externalities, and social networking 
 
According to Porter’s (1998) cluster-based theory of externalities, clusters, 
with its many competing or collaborating across related industries firms, 
tends to trigger innovation and learning processes. As Malmberg and Maskell 
(2002, p.433) point out, “in such environment, chances are greater that an 
individual firm will get in touch with actors that have developed or been 
early adapters of new technology. The flow of industry-related information 
and knowledge is generally more abundant, to the advantage of all firms 
involved”. According to Van der Berg, Braun, and van Winden (2001), most 
definitions of the cluster share the notion of clusters as localized networks of 
specialized organizations (firms and institutions), whose production 
processes are closely linked through the exchange of goods, services and/or 
knowledge. In the social network studies, these actors of a cluster refer to 
“individuals, groups or companies tied by the relationships or flows of 
resources that can be material or non-material” (Wasserman & Faust, 1999, 
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p.4). The resources might include social support, time, information, 
knowledge and expertise sharing, and so on.  
 
 
Figure 1. Interconnections between firms and institutions in a cluster (Menzel & 
Fornahl, 2007) 
 
The role of social capital in linking the main cluster components: technology, 
humans, financing and infrastructure is represented in Figure 2.  
 
 
Figure 2. Social capital and main cluster components 
 
Furthermore, as Audresch (1998) suggests the industries, in which tacit 
knowledge and innovative activity play an important role show a higher 
tendency to spatially cluster. However, there have still very few attempts to 
empirically investigate the role of the spatial dimension in the knowledge 
spillovers. The latter is mainly because tacit knowledge flows are hard to 
track, especially when pure technological externalities are concerned 
(Johansson, 2005).  
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Other factors and processes that influence the spatial and technological 
boundaries of a cluster is the ongoing process of globalization and increasing 
competition in knowledge-intensive sectors. Hence, important knowledge 
sources of the innovation of local firms stem from both local and global 
knowledge linkages. These linkages consist the base on which social capital 
is flourishing enabling all cluster participants to efficiently cooperate with 
one another, which leads to the increased generation of positive externalities 
coming from co-location and building collaborative synergy within the 
cluster, as well as openness for cooperation with other clusters, which leads 
to knowledge spillovers among them and increasing innovations (Bochniarz-
Faoro, 2013). Social networks, both online and real, contribute to increasing 
numbers of contacts between participants sharing common interests and 
create the entire communities. Social networks foster the transfer, diffusion 
of information and knowledge (Bratianu & Orzea, 2013). 
 
 
Dynamic externalities and industry life cycle 
 
Knowledge spillovers and positive externalities from co-location play a 
larger role in industries that are undergoing rapid technological change or 
are in a growing stage of their economic life cycle. There are three types of 
dynamic externalities: the MAR (Marshall-Arrow-Romer), Porter’s, and 
Jacobs`, that allow tracking the role of knowledge flows throughout 
industry’s life cycle (Runiewicz-Wardyn, 2013). The industry life-cycle 
model is based on a stylized description of the evolution of an industry and 
follows the logistics of an S curve, starting with the introduction of new 
products, followed by a period of strong expansion of production, which then 
levels off and eventually leads to a decline. It is possible to assume that 
certain types of dynamic externalities assist the industry as it moves from a 
young to a more mature stage (Figure 3).  
 
Furthermore, new industries – or industries at the introductory stage of 
their development – benefit mostly from diverse knowledge infrastructure 
and inter-industry knowledge spillovers. Therefore, Jacobs’ externalities will 
be more important at this stage. The birth of a new industry typically follows 
radical innovations, which may originate outside of the particular industry 
or sector. Innovation intensity is high, as there are many unexplored 
technological opportunities (Neffke et al., 2009). 
 
At the growth stage of industry development, production becomes more 
standardized, which opens up possibilities for firms to exploit their divisions 
of labor and economies of scale, companies produce more or less similar 
products and get increasingly involved in price competition. This leads 
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typically to a sharp drop in prices and a growth in production volumes. Both 
MAR’s and Jacobs’s externalities may be important at this stage.   
 
At the stage of maturity, firms typically face vigorous price competition. 
Profit margins are reduced and technological opportunities are exhausted. In 
terms of innovation, longer jumps in technology are less likely and 
innovations are more of Arrow’s nature (radical innovations are all but 
infeasible, as the industry has invested heavily in machinery and skill 
development that would become obsolete by dramatic discontinuities in 
technology). The R&D efforts require very specialized, industry-specific 
knowledge and skills. Such expertise is often of a strong tacit nature and is 
best acquired through processes of learning by doing and imitation. The role 
of local possibilities to tailor education, training systems and access to the 
university R&D output increases. Both tendencies lead to a lowering of 
Jacobs’ and an increase of MAR/Porter’s externalities. 
 
Note: *from (1) introductory, (2) growth, (3) maturity and (4) decline phase of industry life cycle 
Figure 3. Industry life cycles* and dynamic externalities 
 
The overview of the literature on industrial life cycle and dynamic 
externalities imply that social networks may be determined by the above-
demonstrated interrelationships between the industry`s maturity process 
and cluster dynamic externalities. Similarly, some mutual linkages between 
the actors within the social network may exhibit more stability than others, 
yet others may transcend cluster boundaries (local networks) and access to 
communication and potential links with other nodes within national, 
international and global value chain networks. Thus, in order to comprehend 
better the interdependencies between clusters, dynamic externalities and 
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social networking the specific industry and its regional contexts must be 
considered. The next section is going to focus on the case of the 
biotechnology industry in the selected EU regions. 
 
 
Biotechnology industry life cycles and drivers of development 
 
The biotechnology industry represents technological evolutions in the 
biopharmaceutical industry, as a whole. The opportunities in the 
biotechnology industry largely mirror those in the pharmaceutical industry1. 
The key difference between the two industries is that biotechnology firms 
are much more focused on research activities because they are still 
developing their initial products. Thus, biotechnology is a relatively young 
branch of bioscience, developed in the late 2000s. According to the 
literature, the biotechnology industry started to form its shape in the early 
1980s. when improved the regulatory and patenting and licensing systems 
and launch government-lead research initiatives, especially in the US. The 
innovation process shows that there is not just one S-curve but a succession 
of S-curves from organic chemistry/pharmacology to biochemistry and 
molecular biology (Figure 4). It can be seen that the waves of molecular 
biology overlap the waves of biochemistry and are about to leap upwards.  
 
 
Figure 4. Industry life cycle maturity and technology diffusion in high-tech 
industries (Runiewicz-Wardyn, 2013) 
 
Currently, scientists and researchers are attempting to exploit basic 
molecular research to identify new drugs, the production of which will be 
                                                   
1 The major difference between biotechnology products and pharmaceuticals is that in case of 
the former drugs are produced in living organisms such as bacteria, yeast and mammalian 
cells, whereas in case of the latter they are produced through a series of chemical synthesis. 
Management Dynamics in the Knowledge Economy | 19 
Vol.5 (2017) no.1, pp.13-31; www.managementdynamics.ro 
    
 
based on recent advances in genomics technology. Scientific breakthroughs 
such as genetic engineering, the ability to create monoclonal antibodies, and 
the mapping of the human genome have opened up new areas of research, 
and the pace of discovery in basic biomedical science has accelerated 
dramatically over the past few decades. The emergence of biotechnology is 
changing the pharmaceutical industry in terms of requiring a convergence of 
science and technologies and a multi-disciplinary approach to producing 
new technological discoveries (biological sciences, chemical engineering, 
bioprocess engineering, information technology, and biorobotics). The latter 
explains the fact that many cluster agglomerations; where biotechnology is 
co-located involve the interaction of such actors as science-based 
universities, global multinationals, health care facilities as well as other 
related industries (chemical, instrumentation, medical, and health research). 
Increasing competition drives the specialization of firms in specific products; 
however, so far this has been somewhat limited due to the few experts in the 
specific biotechnology fields, e.g. cancer diseases. Biotechnology is firmly 
rooted in the growth stage, with heavy reliance on science and R&D 
investments, however, industrial biotechnology is still in its relatively early 
stage of growth, and many potential products are not yet on the market.  
 
Patenting has increased sharply over the past few decades, with 
biotechnology patenting applications far outpacing the general rise in 
patenting applications. The biggest number of patents in biotechnology grew 
from the late 90s up to early 2000. For example, in 1977, there were only 12 
biotechnology patents filed globally under the PCT. By 2009, this number 
had increased up to 9,339 patents (this is substantially more than a 77% 
increase). Almost 70% of these patents were filed by an inventor resident in 
either the EU-27 or US (OECD, 2012). 
 
The level of activity in the biotechnology industry among the EU countries 
depends largely on the research field. For example, Europe’s competitive 
edge lies mainly in healthcare applications and in industrial biotechnology, 
including the chemical industry. Some Member States have developed 
advanced biotech sectors whereas others have stayed behind (Denmark, 
Germany, UK). New Member States of the EU are generally the early movers 
in the biotechnology sector. Thus, the identification of the stage of life cycle 
of the biotechnology industry must be treated with necessary caution. 
 
However, while the biotechnology sector shows a strong growth stage, the 
degree of diffusion and adoption of biotechnology products and processes 
has been slowed down for several reasons. Mainly, the substitution of 
traditional techniques for producing products with the use of biotechnology 
relates to the costs of the transformation of existing production processes, 
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e.g. substituting diesel extracted from petroleum with biodiesel made from 
feedstock or canola oil (McNiven, 2007). Moreover, in the present case of 
biopharmaceuticals, the demand side is largely influenced by regulations. It 
is strongly regulated and therefore excludes many inventions due to 
morality (European Patent Office, 2016).  
 
 
Mapping biotechnology clusters in the EU 
 
The major share of the biotechnology firms is concentrated in 
“biotechnology clusters” mostly located in western and northern European 
regions or countries with a long tradition of life sciences and biotechnology 
research and activities in industries such as pharmaceutical, chemical, agro-
production and medical technology. Biopharmaceutical employ over 2 
million people in the EU. It is among the largest sectors supported by cluster 
organizations. These clusters are often located around research institutions 
and universities. These organizations form a highly attractive infrastructure 
both for scientists and for specialized suppliers of materials, equipment, and 
services. The reason for being part of these networks is the diversification of 
costs and risks of developing new technologies and the innovative 
environment. Investments and acquisitions of university biotech spin-offs 
accelerate the location advantages of some clusters and regions, generating a 
positive dynamic for growth (Todeva & Rakhmatullin, 2016).  
 
Map 1. The EU regions specializing in biopharmaceuticals and their leading 
universities (European Cluster Observatory, 2016) 
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Map 1 shows the EU locations specializing in biopharmaceuticals and their 
leading universities. These regions were much more successful in providing 
a “critical mass” for encouraging research and enhancing networking 
between business, higher education institutions, research centers, and 
technology parks. As a result, they follow the virtuous circle of growth – 
innovations and technological change is fueling economic growth, which is 
being fed back into higher earnings and greater investment in education and 
R&D. 
 
 
Dynamic externalities in the biotechnology industry 
 
The analysis of the growth stage of biotechnology shows that the industry is 
still in the initial stage of growth in its life cycle. This requires huge amounts 
of R&D funding, whereas R&D projects often involve a high risk of failure. 
Biotech firms that are active in the biopharmaceutical sector and do not have 
alliances with large pharmaceutical firms, tend to rely more heavily on 
domestic sources in their innovative activities, including universities and 
public research organizations. Thus, in order to stimulate positive 
technological externalities in the biotechnology industry, the local 
productive structure must be determined by the presence of diversified local 
technological capability centers (clustered near universities).  
 
Furthermore, the rate of innovation in biotechnology depends on the strong 
interaction with science-based university research and on the presence of 
other industries, such as pharmaceutical, chemical, healthcare, food, etc. 
Furthermore, because most European companies specializing in 
biotechnology are small or medium-sized enterprises (SMEs). Therefore, the 
rivalry is extremely intense. High research costs, the need to fully exploit 
patent protections before they expire, and the expenses of costly marketing 
induce close alliances and co-operation among biotech firms and R&D 
institutions. In fact, the study by Runiewicz-Wardyn (2013) shows that both 
agglomeration economies and the proximity to a qualified labor pool as well 
as other biotechnology firms have a positive and significant impact on 
biotechnology patents. Other researchers have reached a similar conclusion. 
For example, Prevenzer (1997) shows that in biotechnology firms tend to 
cluster together in just a handful of locations. The above arguments suggest 
the existence of earlier described Porter externalities in the EU 
biotechnology clusters. 
 
Furthermore, the results of Runiewicz-Wardyn’s (2013) study indicate that 
diversity across complementary economic activities is very conducive to 
innovation in the biotechnology industry. Biotechnology companies 
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especially those whose success depends on staying on top of new 
technologies and processes, increasingly want to be where new, hot ideas 
are percolating. This suggests patenting in biotechnology requires combining 
innovative specialization with industry diversity. The latter could also 
suggest Jacobs’s (1969) externalities. Except for the fact that Jacobs (1969) 
and Porter (1998) argue the opposite, Porter (1998) considers that 
competition is more conducive to knowledge externalities than a local 
monopoly would be. It should be emphasized that by local competition, 
Jacobs (1969) refers to the competition for new ideas embodied in economic 
agents. An increased number of firms provide greater competition for new 
ideas, but greater competition across firms facilitates the entry of new firms 
specializing in some new product niche. This is because the necessary 
complementary inputs and services are likely to be available from small, 
specialist niche-oriented firms but not necessarily from large, vertically 
integrated producers. Large firms play a pivotal role also in driving 
innovation, but share this role with small technology and service firms, 
which sometimes operate under the radar (Todeva & Rakhmatullin, 2016).  
 
In sum, the rate of innovation in biotechnology depends on to a large extent 
on specialization and cooperation among large pharmaceutical firms and 
small, research-intensive institutions, biotechnology enterprises. 
Agglomeration externalities in the sense of Jacobs’s resulting from inter-
industry knowledge spillovers turned out to be especially important in the 
biotechnology industry in its early growth phase. Further on, the innovative 
activity of biotechnology firms is determined by a combination of both 
innovative specialization, industry diversity and competition externalities.  
 
Local knowledge spillovers and universities-industry collaborations 
 
It`s been already pointed out in the previous section of the paper that 
different agglomeration externalities are needed in various stages of 
biotechnology industry life-cycle. Even though the dynamic externalities 
approach seems to be very useful in explaining cluster development, some 
scholars link the emergence of high-tech clusters rather to spin-off activities 
than agglomeration externalities (Boschma, 2014).  
The role of the university was already acknowledged in Michael Porter`s 
cluster diamond model, mapping four interactive dimensions that impact 
cluster competitiveness. The latter are the factor conditions, demand 
conditions, firm strategy and rivalry, and supporting industries. Universities 
are one such factor. On the one hand, universities also influence other 
dimensions of cluster competitiveness, e.g. increasing the quality of inputs, 
upgrading human capital, disseminating knowledge and generating new 
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technological opportunities. In fact, many platform technologies for the new 
biotechnology companies have been started with basic research programs 
run in the university labs.  
In fact, universities and their research centers play a “catalytic role” in the 
process of regional development and thus influence knowledge-based 
economic development (Ketikidis et al., 2016). Most of the knowledge 
universities produce may flow and spill over to the local economy by means 
of university-industry transfer projects, university spin-offs, and the mobility 
of university graduates and researchers to industry and social networks. 
Trained science and technology (S&T) graduates look for their first jobs in an 
area of the university. In fact, Bekkers and Freitas (2008) conclude that labor 
mobility is very important for the transfer of academic technological 
‘breakthroughs’ into the biotechnology industry in Dutch universities (PhDs 
and academic staff). Zucker, Darby and Armstrong (2002) report that 
biotechnology firms that collaborate with ‘star’ scientists are more likely to 
be productive in terms of a number of patents. On the one hand, doctoral 
S&T graduates of pharmaceutical or engineering industries employ their 
academic knowledge in industry; on the other hand, they learn from their 
training in laboratories in large corporations. 
Audretsch and Stephan (1996) points that the discovering scientists 
(‘superstars’) tend to enter into contractual arrangements with existing 
firms (contract or ownership) or start their own firm in order to extract the 
supra-normal returns from the fruits of their intellectual human capital. 
Moreover, the scientist works with or create a new firm within commuting 
distance of home or university (where they tend to retain affiliation) thus 
creating localized effects of university research.  Similarly, in terms of R&D 
collaborations and knowledge networking in the biotechnology, local 
knowledge spillovers and nationally based R&D institutions and business 
entities seem to play a significant role and thus confirms the general features 
of a strong spatial concentration of the biotechnology industry.  
 
Aharonson, Baum, and Feldman (2004) emphasize consistently that 
proximity to universities and/or other local sources of knowledge is 
important for the circulation of tacit knowledge and that personal 
acquaintance with the scientists, continuous monitoring of companies are 
fundamental aspects of venture capital and this knowledge is much easier to 
be acquired at the local level. The discovering scientists (‘superstars’) tend to 
enter into contractual arrangements with local firms (contract or ownership) 
or start their own firm in order to extract the supra-normal returns from the 
fruits of their intellectual human capital. Moreover, the scientist works with 
or create a new firm within commuting distance of home or university 
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(where they tend to retain affiliation) thus creating localized knowledge 
spillovers. Access and ability to use (and integrate) external knowledge 
becomes increasingly important for growth and diversification (Corelleur, 
Carrere, & Mangematin, 2003; Lemariè, Mangematin, & Torre, 2001). 
 
In other terms of a secrecy of knowledge sharing localized effects of 
university and industry research are most likely to result primarily from a 
combination of tacit non-replicable knowledge and low geographical as well 
as organizational mobility of researchers (Breschi & Lissoni, 2001). 
Furthermore, the interviews with EU biotechnology field experts in 2011 
conducted by Runiewicz-Wardyn (2013) have shown the importance of IP 
protection and secrecy in R&D projects. They emphasized the importance to 
publish all the R&D output, prior to discussing them in public or in an 
informal way. Some knowledge tends to remain sticky and limited in its 
circulation. Naturally, excludable and rivalries knowledge do not spill over, it 
is rather people embodying knowledge move (locally) across organizations 
in order to exploit the value of their knowledge.  
 
The role of local research base and spin-offs in the EU biotechnology 
industry – the overview of the empirical studies results 
The following two sections present the research conclusions based on the 
review of over 30 different research papers and articles, aiming to identify 
the knowledge spillovers, the role of networks and collaborations and 
dynamic externalities in the biotechnology clusters in the EU. The method 
applied by the authors included both case study and/or econometric 
analysis. 
 
The study results by Prevezer (2003), Aharonson et al. (2004), Corelleur at 
al. (2003) and Swann and Prevezer (1996) show that access and ability to 
use (and integrate) external and local knowledge becomes increasingly 
important for growth and diversification in biotechnology clusters. Similarly, 
Pammolli and Riccaboni (2001) conclude, in their analysis of the European 
biotechnology clusters, that clustering derives to a large extent by the 
availability of a strong, heterogeneous but integrated research base that 
facilitates the transfer and the integration of knowledge, as well as the 
development of skilled labor, the mobility of such labor and – presumably – 
also the development of other supporting institutions like venture capital 
(Table 1). 
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Table 1. The overview of the research studies results on cluster development in 
biopharmaceutical sector in the EU based on the literature (for the period 1997-
2013) 
EU biotechnology industry 
Role of university spin-offs Local research base 
1) many new biotechnology firms in 
the EU15 are university spin-offs 
(which are at the initial stage of 
development in the New EU Member 
states). 
2) successful clusters exhibit high 
rates of internal firm’s formation, 
whereas weaker clusters are 
characterized by lower domestic 
productivity and higher propensity to 
migrate. 
3) process of a spinoff from local 
institutions originates and sustains 
the cluster.  
4) spinoffs and startups tend to locate 
close to their “parents” and region-
specific practices/ways of doing 
things. 
1) local sources of knowledge appear to be 
fundamental in the early stages of cluster 
development and for new, highly 
specialized firms.  
2) access to external and inter- regional 
knowledge becomes important for growth 
and diversification. 
3) firms collaborate with ‘star’ scientists, 
PhDs and academic staff, especially in the 
case of very specific, narrow fields. 
4) strong, heterogeneous but integrated 
research base facilitates 
knowledge/technology transfer. 
5) pharmaceutical firms, which perform 
basic research in close cooperation with 
academia produce more patents.  
Many new biotechnology firms in the EU15 are university spin-offs, in the 
New Member states spin-offs are at the initial stage of development. 
Consequently, successful clusters continue to exhibit high rates of internal 
firm’s formation, whereas weaker clusters are characterized by both lower 
domestic productivity and higher propensity to migrate. Moreover, spinoffs 
and startups tend to locate close to their “parents, therefore the process of a 
spinoff from local institutions originates and sustains the cluster. 
 
Furthermore, local sources of knowledge appear to be especially important 
in the early stages of the development of a cluster and for new, highly 
specialized firms. Whereas access and ability to use (and integrate) 
external/pan-European/global knowledge become increasingly important 
for growth and diversification (Corelleur et al., 2003; Lemariè et al., 2001; 
Prevezer, 2003;  Swann & Prevezer, 1996). 
 
Networks and collaborations in the EU biotechnology industry - the 
overview of the empirical studies results 
A number of authors have commented upon the growing importance of 
social networks and collaboration in achieving innovation capacity (Mowery, 
1988). Less understood are the mechanisms by which such networks 
emerge. In terms of the character of networks, the case studies based on the 
26 | Malgorzata RUNIEWICZ-WARDYN 
Dynamic Externalities, Universities and Social Capital Formation in the EU Biotechnology 
Industry 
 
EU clusters (Van Egeraat & Curran, 2010) show that both the formal 
networks, connected through patents, and the informal networks, connected 
through directorship do exist. However, the formal network is noticeably 
less clustered than the informal network, which suggests knowledge in the 
formal network will flow and diffuse in a different, slower manner.  The 
complex and interdisciplinary nature of relevant knowledge bases in 
pharmaceutical R&D tends to make technological innovations the outcome of 
interactions and cooperation among different types of agents commanding 
complementary resources and competencies. The formal network is 
noticeably less clustered than the informal network, which suggests that the 
informal networks are far more conducive to knowledge flow than the 
formal networks.   
 
Owen-Smith, Riccaboni, Pammolli and Powell (2002) compare the structure 
of the American and European networks in biomedical research. They show 
that the US network is characterized by extensive relationships between U.S. 
public research organizations and firms located in dense regional clusters 
that span therapeutic areas, across multiple stages of the development 
process, and involve diverse collaborators. In contrast, European innovative 
networks are characterized by sparser, more specialized and upstream 
relationships among a more limited set of organizational participants located 
in national clusters (Table 2). Both U.S. and European networks are 
geographically clustered, then, but in quite different manners. 
 
Table 2. The overview of the research studies results on knowledge spillovers 
and networks in the EU biotechnology industry (for the period 1997-2013) 
Knowledge spillovers Networks and collaborations 
 
Character of 
networks 
 
Degree of 
diversity 
 
Geographical 
dimension of 
networks 
1) proximity to 
universities is 
important for tacit 
knowledge, sharing 
R&D opportunities and 
personal acquaintance. 
2) superstars enter into 
contractual 
arrangements with 
existing firms (contract 
or ownership) or start 
their own firm (to gain 
supra-normal returns);  
3)scientist work with 
1) cooperation 
among different 
types of agents of 
complementary 
resources and 
competencies. 
2) links between 
distinct clusters in 
the network. 
3) networking and 
informal contacts 
more important at 
the early stage of 
R&D process 
1)networks 
are 
characterized 
by sparser, 
more 
specialized 
and upstream 
relationships 
among a 
limited set of 
organizational 
participants 
located in 
national 
1) strong 
geographical 
dimension spanning 
well beyond the 
boundaries of the 
location. 
2) openness to 
geographical distant 
nodes: increasing 
number of 
collaborations and a 
decreasing 
proportion of local 
connections. 
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or create a new firm 
within commuting 
distance of home or 
university (of 
affiliation) creating 
localized effects of 
research. 
whereas further 
knowledge sharing is 
determined by the 
importance of IP 
protection and 
secrecy. 
4) formal network is 
noticeably less 
clustered than the 
informal network. 
 
 
clusters. 
 
3) better-performing 
and growing firms 
rely less on local 
sources of 
knowledge.   
4) inter-
organizational 
collaboration 
follows the 
accumulative 
advantage based on 
the overlapping 
specialization, and 
multi-connectivity.  
5) network tends to 
consolidate around a 
rather stable core of 
companies, 
composed by large 
incumbents and 
early entrants in the 
network. 
 
Networks span well beyond the boundaries of the geographical location, but 
the performance of the individual nodes within the network is strongly 
associated with high degrees of openness to geographical distant nodes 
(Owen-Smith et al. 2002; Pammolli & Riccaboni, 2001). Moreover, in a 
dynamic perspective, the growth of geographical networks and the tendency 
towards clustering is accompanied by a parallel process of increasing 
openness of the original clusters. In Europe, recent trends suggest a 
combination of an increasing number of collaborations and a decreasing 
proportion of local connections (Pammolli & Riccaboni, 2001). Similarly, in 
the USA biotechnology clusters rely increasingly less on local sources of 
knowledge (Corelleur et al., 2004).  In a similar way, Powell, Porter and 
Whittington (2005) conclude that biotechnology clusters in the EU follow the 
accumulative advantage based on the overlapping specialization and multi-
connectivity. For example, international cluster networks can help setting up 
cluster initiatives by transferring the experience of more mature clusters to 
emerging ones. An example can be drawn from the Connecting Energy 
Clusters across Europe project (CENCE). The CENCE consortium played a 
vital role in the development of a new Bioenergy Innovation Cluster in 
Northern Hungary. Embedded in international co-operation, local clusters 
receive practical advice and support in structuring and managing the new 
cluster organization from the start.   
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Summary and conclusions 
 
The main research questions addressed in this paper concerns the role of 
dynamic externalities, university-industry linkages and role of social 
networking in facilitating the development of the EU biotechnology industry. 
For this purpose, the author adopted contributions from the industry life-
cycle theory, theory clusters, and dynamic externalities as well as the social 
capital literature. Globally these research results contribute to on-going 
debates in the area of high-tech clusters formation and development, social 
networks and university-industry linkages, both at the methodological and 
empirical levels. The results obtained, although still exploratory, already 
provide some indications concerning a preferable condition for the EU 
biotechnology industry to develop and prosper. The development of 
biotechnology industry in the EU is attributed to both agglomeration 
externalities and the presence of leading universities and research 
laboratories. The results of the study show that the interaction and 
collaboration are of particular importance to the EU biotechnology industry, 
especially for the SMEs, for securing financial resource, business platforms, 
and infrastructure required for biotechnology research or business 
development. The EU biotechnology industry relies very much on university-
business R&D partnerships and research mobility as knowledge-diffusion 
channels. The research further supports the view of Todeva and 
Rakhmatullin (2016) that building an effective triple helix of proactive public 
authorities, universities and business enterprises is a prerequisite for the 
development and implementation of smart specialization strategies through 
interregional cooperation at European level.  
 
The results confirm the general features of a strong spatial concentration of 
the biotechnology industry. Social networking and informal contacts seem to 
be a more important at the early stage of R&D process, whereas in terms of 
further knowledge sharing experts emphasized the importance of IP 
protection and secrecy in R&D process; and therefore the importance to 
publish all the results, prior discussing them in public or in an informal way. 
The R&D collaborations and knowledge networking in the home region and 
nationally based R&D institutions and business entities seem to play a more 
significant role for the newer EU member states. For many R&D units, EU 
ERA-NET-based R&D funding plays only a secondary role. The latter fact 
shows that the actual ability of regional R&D units to participate and take 
advantage of knowledge networks (locally or/and globally) depends largely 
on their own stock of knowledge and absorptive capacities. 
 
In terms of the further research, several questions should be considered. For 
example, what regional local externalities favor job mobility in the 
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biotechnology industry or how do social networks fit into the larger debate 
around the development of biotechnology technology clusters? Furthermore, 
if cluster development depends on the formation of social networks that 
have primary origins through shared career experiences, then what could be 
the role for government institutions in favoring such networks? These 
questions are important and should be further developed in the research.  
 
In terms of policy recommendations, it is essential to encourage the EU 
Member States to consider the role of universities and social capital in their 
regional/ local innovation systems, especially when drafting smart 
specialization strategies. Furthermore, analysis how universities are being 
involved in smart specializations, including sharing experiences and best 
practices of university-regional engagement across the EU, match the 
technical and academic profiles of local universities with the economic 
priorities of the region as well as study the existing relationships between 
the university, individual academics and other regional actors to ‘nourish’ 
the partnerships. Last, but not least, understand the specific obstacles and 
challenges that inhibit a greater level of engagement of local universities in 
the region. 
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